Abstract
The timing of parturition is crucial for neonatal survival and infant health. Yet, its genetic basis remains largely unresolved. We present a maternal genome-wide meta-analysis of gestational duration (n = 195,555), identifying 22 associated loci (24 independent variants) and an enrichment in genes differentially expressed during labor. A meta-analysis of preterm delivery (cases = 18,797, controls = 260,246) revealed 6 associated loci, and large genetic similarities with gestational duration. Analysis of the parental transmitted and non-transmitted alleles (n = 136,833) shows that 15 of the gestational duration genetic variants act through the maternal genome, while seven act both through the maternal and fetal, and two act only via the fetal genome. Finally, the maternal effects on gestational duration show signs of antagonistic pleiotropy with the fetal effects on birth weight: maternal alleles that increase gestational duration have negative fetal effects on birth weight.
Competing Interest Statement
As of January 2020, A.M. is an employee of Genentech, and a holder of Roche stock. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. M.I.McC. has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, M.Mc.C. is an employee of Genentech, and a holder of Roche stock. D.A.L. receives support from several national and international government and charitable research funders, as well as from Medtronic Ltd and Roche Diagnostics for research unrelated to that presented here. H.S. obtained speaker fees from Ferring Pharmaceuticals, Merck A/S, AstraZeneca, Cook Medical. V.S., G.T., G.S., D.F.G., U.T. and K.S. are employees of deCODE genetics/Amgen.
Funding Statement
B.J. received funding from The Swedish Research Council, Stockholm, Sweden (2015-02559), The Research Council of Norway, Oslo, Norway (FRIMEDBIO #547711, #273291), March of Dimes (#21-FY16-121). Research reported in this publication (B.J., G.Z. and R.F.) was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number R01HD101669. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. G.H.M has received funding from the Norwegian Diabetes Association and Nils Normans minnegave. G.H.M. is supported by the Norwegian Research Council (Postdoctoral mobility research grant 287198). M.C.B's contribution to this work was supported by a UK Medical Research Council (MRC) Skills Development Fellowship (MR/P014054/1) and a University of Bristol Vice-Chancellor's fellowship. M.C.B and D.A.L are supported by the British Heart Foundation (AA/18/7/34219) and work in a Unit that receives funding from the University of Bristol and UK Medical Research Council (MRC) (MC_UU_00011/6). MV is supported by the Research Council of Norway (project #301178). D.A.L is supported by a British Heart Foundation Chair (CH/F/20/90003). S.F.A Grant is supported by Daniel B. Burke Chair for Diabetes Research and NIH Grant R01 HD056465. IDF to CAG center from CHOP; CHOP's Endowed Chair in Genomic Research. Funding for T.L was provided by the European Regional Development Fund and the programme Mobilitas Pluss (MOBTP155). B.S is a core member of the NIHR Exeter Clinical Research Facility. R.M.F and R.N.B were funded by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (WT104150). R.M.F. is funded by a Wellcome Trust Senior Research Fellowship (WT220390). B.F was supported by the Oak Foundation. L.B is a senior research scholar from the Fonds de la recherche du Quebec en sante (FRQS) and member of the CR-CHUS, a FRQS-funded Research Center. Dr. Oken has received funding from the US National Institutes of Health. D.W.E. is funded by the Novo Nordisk Foundation(NNF18SA0034956, NNF14CC0001, NNF17OC0027594).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Statements of approval by ethics oversight bodies are detailed for each study in the Supplementary Text.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update methods and results sections.
Data Availability
Cohorts should be contacted individually for access to raw genotype data, as each cohort has different data access policies. Summary statistics from the meta-analysis excluding 23andMe and the summary statistics of the top 10,000 SNPs for each phenotype will be made available at the EGG website (https://egg-consortium.org/). Access to the full set, including 23andMe results, can be obtained after approval from 23andMe is presented to the corresponding author or by completion of a Data Transfer Agreement (https://research.23andme.com/dataset-access/), which exists to protect the privacy of 23andMe participants. Access to the Danish National Birth Cohort (phs000103.v1.p1), Hyperglycemia and Adverse Pregnancy Outcome (phs000096.v4.p1), and Genomic and Proteomic Network (phs000714.v1.p1) individual-level phenotype and genetic data can be obtained through dbGaP Authorized Access portal (https://dbgap.ncbi.nlm.nih.gov/dbgap/aa/wga.cgi?page=login). The informed consent under which the data or samples were collected is the basis for determining the appropriateness of sharing data through unrestricted-access databases or NIH-designated controlled-access data repositories. The summary statistics used in this publication other than the one generated are available at the following links: fetal GWAS of gestational duration (https://egg-consortium.org/), fetal and maternal GWAS of gestational duration (https://egg-consortium.org/), miscarriage (http://www.geenivaramu.ee/tools/misc_sumstats.zip), age at first birth, oestradiol (women), endometriosis, number of live births and age at menarche (http://www.nealelab.is), age at menopause (https://www.reprogen.org), testosterone (women) 49, SHBG, testosterone and CBAT (https://doi.org/10.6084/m9.figshare.c.5304500.v1), pelvic organ prolapse and leiomyome of the uterus (https://www.finngen.fi/fi), polycystic ovary syndrome (https://www.repository.cam.ac.uk/handle/1810/283491 and https://www.finngen.fi/fi) and pre-eclampsia (European Genome-phenome Archive, https://ega-archive.org, EGAD00010001984). Pan-UK Biobank data is available at https://pan.ukbb.broadinstitute.org/. For pre-computed LD scores for European populations (https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2). g:Profiler, https://biit.cs.ut.ee/gprofiler/gost.
